Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study.

Brik, Riva; Butbul-Aviel, Yonatan; Lubin, Sari; Ben Dayan, Eliad; Rachmilewitz-Minei, Tamar; Tseng, Lillian; Hashkes, Philip J

Brik, Riva; Butbul-Aviel, Yonatan; Lubin, Sari; Ben Dayan, Eliad; Rachmilewitz-Minei, Tamar; Tseng, Lillian; Hashkes, Philip J.

Affiliation

Brik R; Meyer Children's Hospital, Rambam Medical Center, Haifa, Israel.

Arthritis Rheumatol ; 66(11): 3241-3, 2014 Nov.

Article in En | MEDLINE | ID: mdl-25049046

Subject(s)

Antibodies, Monoclonal/therapeutic use; Colchicine/therapeutic use; Drug Resistance; Familial Mediterranean Fever/drug therapy; Interleukin-1beta/immunology; Adolescent; Antibodies, Monoclonal, Humanized; Blood Sedimentation; C-Reactive Protein/metabolism; Child; Dose-Response Relationship, Drug; Familial Mediterranean Fever/metabolism; Female; Humans; Male; Outcome Assessment, Health Care; Pilot Projects; Time Factors; Treatment Failure; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Familial Mediterranean Fever / Drug Resistance / Colchicine / Interleukin-1beta / Antibodies, Monoclonal Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Arthritis Rheumatol Year: 2014 Document type: Article Affiliation country: Israel Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google